Partnership Aims to Uncover Novel Therapies for Developmental and Epileptic Encephalopathies
Why is the discovery of new therapies for genetic epilepsies so critical? Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience, a discovery technology and therapeutics company, have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. This partnership brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s expertise in brain health and epilepsy drug development.
The multi-year agreement will see Quiver receive an undisclosed advance payment and support for defined research activities, along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data. Quiver is also eligible to receive additional milestone payments of up to $120 million and royalties upon Angelini’s election of drug targets identified through the collaboration.
Key Insights at a Glance
- Collaboration Terms: Quiver will receive an undisclosed advance payment and support for research activities, with additional licensing fees and milestone payments of up to $120 million.
- Technology Integration: Quiver’s platform uses human neuronal models, single-cell transcriptomic resolution, optical electrophysiology, and AI to accelerate the discovery of precision therapies.
- Target Diseases: The partnership aims to address Developmental and Epileptic Encephalopathies (DEEs), a group of rare diseases affecting children worldwide.
- Strategic Importance: This collaboration is part of Angelini Pharma’s strategic priorities to strengthen its global presence and expand its pipeline of innovative medicines.
Why the Unmet Need for Genetic Epilepsy Therapies Is Urgent
Despite recent advancements, the treatment landscape for genetic epilepsies remains fraught with challenges. Developmental and Epileptic Encephalopathies (DEEs) are a group of rare diseases affecting children, causing a spectrum of neurodevelopmental symptoms and severe treatment-resistant seizures linked to genetic mutations. The functional and molecular consequences of these mutations are not well understood, leaving a significant unmet need for more effective therapies. This collaboration aims to generate novel scientific insights and accelerate the discovery of precision therapies, addressing a critical gap in the market.
Why the Window for Action Is Closing Fast
Just as a race against time, Angelini Pharma and Quiver Bioscience are working diligently to bring new treatments to market. The urgency is palpable, as children affected by DEEs face lifelong challenges without effective interventions. By leveraging Quiver’s advanced technology platform and Angelini Pharma’s expertise, the partnership is poised to make significant strides in understanding and treating these complex conditions. The next steps include extensive research and clinical trials to validate the identified drug targets and bring them to patients in need.
Angelini Pharma Mobilizes Advanced Technologies to Tackle Genetic Epilepsies
Angelini Pharma is committed to advancing the discovery and development of novel therapies for genetic epilepsies. Angelini Pharma will leverage Quiver’s technology platform to gain deeper insights into the molecular and functional consequences of genetic mutations associated with DEEs. “The prospects of our collaboration with Quiver Bioscience are very promising,” said Rafal Kaminski, MD, PhD, Chief Scientific Officer at Angelini Pharma. “The aim is to generate novel scientific insights on a scale and richness that has been unprecedented in this area of research.” The partnership will integrate cutting-edge technologies and advanced data analytics approaches, including AI, to generate a unique data set that will inform the development of novel therapies.
Future Outlook
The journey to developing new treatments for genetic epilepsies is akin to navigating a complex maze, where each step forward brings hope to those affected. Angelini Pharma and Quiver Bioscience are at the forefront of this journey, with a clear goal to discover and develop differentiated therapeutics that can address multiple DEEs. The collaboration is expected to yield significant scientific breakthroughs, potentially transforming the lives of children and families impacted by these rare and debilitating conditions.
Conclusion
The collaboration between Angelini Pharma and Quiver Bioscience represents a significant step forward in the fight against genetic epilepsies. By combining advanced technologies and deep expertise, the partnership aims to address the pressing unmet need for more effective therapies. This strategic move underscores Angelini Pharma’s commitment to innovation and global leadership in brain health. Join the conversation in the comments below.
About Quiver Bioscience
Quiver Bioscience is a technology-driven biotechnology company focused on accelerating discovery of empirically grounded, AI-driven therapeutics that deliver transformative value to patients with neurological disease. Quiver has built the first-of-its kind perturbation atlas of neuronal behavior using its proprietary Genomic Positioning System (GPS) platform, enabling precise target identification, functional validation, and safety assessment. Their empirical-in-a-loop approach integrates scalable human neuronal models, advanced single-cell optical electrophysiology and multi-omics techniques, with machine learning and surrogate models, to identify novel therapeutic targets and optimal candidate molecules.
About Angelini Pharma
Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups.
About Angelini Industries
Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates.
Source link: https://www.businesswire.com/
